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A Yellow Fever Epidemic
A New Global Health Emergency?
The worst yellow fever epidemic in Angola since 1986
is rapidly spreading, including the capital, Luanda. In
Angola, the epidemic began in December 2015 and the
laboratory-confirmed outbreak was reported to
the World Health Organization (WHO) on January 21,
2016.1 Angola has had 2023 suspected cases and 258
deaths as of April 26, 2016.1 China, the Democratic
Republic of Congo, and Kenya also have reported cases
arising from infected travelers from Angola. Namibia and
Zambia also share a long border with Angola, with considerable population movement between the countries. Similar to other recent epidemics, quick and effective action to stop the spread of yellow fever is the
responsibility of the world’s health community.
More than 7 million Angolans have been vaccinated, but supply shortages could potentially lead to a
health security crisis if yellow fever spreads within
Africa, Asia (which has never experienced a yellow
fever epidemic), or the Americas (where Aedes mosquito vectors transmit yellow fever as well as Zika,
dengue, and chikungunya). The Pan American Health
Organization declared an epidemiological alert on April
22, 2016, for yellow fever in Latin America.2 The WHO
should urgently convene an emergency committee to
mobilize funds, coordinate an international response,
and spearhead a surge in vaccine production. Prior

Memphis, Tennessee; and in 1905 in New Orleans,
Louisiana) and in Europe in 1730 and 1821.
After an incubation period of 3 to 6 days, an acute
febrile phase occurs with myalgia, headache, back pain,
anorexia, nausea, and sometimes vomiting; symptoms
typically resolve within 1 week. In approximately 1 in 7
individuals, a second phase quickly follows with high fever, jaundice, bleeding, and kidney damage, with death
occurring in 50% of patients; most of the remaining half
fully recover.4 Each year, yellow fever causes an estimated 30 000 deaths, mostly in Africa.4
Even with knowledge of the typical clinical manifestations and outbreak epidemiology, clinical diagnosis can be difficult because yellow fever can mimic multiple febrile illnesses, including those causing jaundice
and bleeding (such as acute viral hepatitis and viral hemorrhagic fevers). Laboratory diagnostic tests can detect the virus and specific antibodies in the blood. No
specific antiviral drug or immune therapy exists for yellow fever disease.

The Yellow Fever Vaccine

A licensed, live attenuated, yellow fever vaccine has been
available for decades, conferring lifelong protection
within 10 days in more than 90% of individuals who received the vaccine.4 National border rules currently
require a yellow fever card showing proof
of vaccination within 10 years for epideSimilar to other recent epidemics, quick
miologically at-risk travelers. Although
the yellow fever vaccine is well tolerand effective action to stop the spread
ated, it is not recommended in nonepiof yellow fever is the responsibility
demic settings for individuals with severe immunodeficiency, pregnant
of the world’s health community.
women, infants, or individuals with sedelays by the WHO in convening emergency commit- vere egg allergies. Individuals older than 60 years are at
tees for the Ebola virus, and possibly the ongoing Zika higher risk for a rare, but serious complication, vaccineepidemic, cost lives and should not be repeated.3 Act- associated viscerotropic disease. The WHO recoming proactively to address the evolving yellow fever epi- mends routine vaccination for children living in at-risk
demic is imperative.
countries for yellow fever, with community immunity
conferred by vaccination rates of 60% to 80%.4
Epidemiology and Diagnosis of Yellow Fever
Mass vaccination campaigns in conjunction with
The yellow fever virus is an arbovirus that belongs to mosquito control, surveillance, and coordinated rethe flavivirus genus (like Zika, dengue, and West Nile). sponses are urgently needed in the event of an out(Yellow refers to jaundice caused by liver involvement.) break. The WHO serves as the Secretariat for the InterThe virus is transmitted between humans and from national Coordinating Group for yellow fever vaccine
monkeys to humans by mosquitoes, primarily by Aedes provision, with partners such as the United Nations (UN)
(aegypti) and Hemogogus, in 1 of 3 cycles: (1) urban Children’s Fund, the International Federation of Red
yellow fever, (2) jungle (sylvatic) yellow fever, and Cross and Red Crescent Societies, and Doctors Without
(3) intermediate yellow fever. More than 500 million Borders (Médecins Sans Frontières).4 The Internaindividuals are at risk in Africa, as are approximately tional Coordinating Group maintains a vaccine stock400 million individuals in Latin America.4 Historically, pile for rapid response; however, a serious vaccine shortwell-described outbreaks occurred in the United States age is anticipated if yellow fever spreads to other
(eg, in 1793 in Philadelphia, Pennsylvania; in 1878 in countries or regions. Surge capacity is currently limited
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because specific pathogen-free chicken eggs are needed to produce the vaccine.
On May 2, 2016, the Democratic Republic of Congo announced plans to vaccinate nearly 2 million individuals in Kinshasa
and Kongo Central, suspecting local transmission.5 This campaign,
along with Angola, could be a tipping point in exhausting global vaccine supplies.
The WHO’s Emergency Use Assessment and Listing (EUAL) procedures, first introduced for the Ebola virus,6 could be adapted to
safeguard the yellow fever vaccine supply. International experts have
urged using one-fifth of the normal vaccine dose in Angola to avert
acute shortages if the virus spreads.7 If this suggested practice is
carried out, regulatory hurdles would likely be encountered, and
there would also be uncertainty regarding the extent and duration
of immunity, especially in children. Monath et al7 recently recommended “invoking the EUAL [procedures] now, rather than waiting
for a major yellow fever vaccine shortage to occur.” Stewardship of
scarce vaccine supplies is essential, but requires the WHO’s directorgeneral to declare a public health emergency of international concern or determine it is “in the best interest of public health.”6 Given
the world’s vital health security interests, the WHO’s directorgeneral should use EUAL procedures to authorize a reduced vaccine dose to control the epidemic in Angola.

Time to Convene an Emergency Committee
It is only by convening an emergency committee that the WHO’s
director-general could declare a public health emergency of international concern. Whether this emergency committee recommends declaring a public health emergency of international concern, it would advise the WHO’s director-general on responding to
ongoing and future yellow fever outbreaks. There are strong reasons to convene an emergency committee now. The looming threat
of a severe yellow fever vaccine shortage exists amid epidemics in
Africa, and potentially in Latin America and Asia. Even if the emergency committee does not recommend a public health emergency
of international concern, it could recommend invoking EUAL procedures for use of a reduced vaccine dose.
Among multiple needed steps, the WHO’s director-general
(based on the emergency committee’s advice) should convene and
coordinate stakeholder meetings with yellow fever vaccine manufacturers to catalyze a surge in production; incentivize and coordi-

Going Forward: A Standing Emergency Committee
The WHO has responded much more quickly to this yellow fever epidemic than with either the Ebola virus or even the Zika virus. The
WHO’s director-general traveled to Angola in early April, working with
international partners to roll out a mass yellow fever vaccination
campaign—expressing the concern that “the whole world could be
at risk” of a yellow fever epidemic. Global health advocates should
not have to call for convening an emergency committee for each new
international health threat. Instead, the WHO should establish a
standing emergency committee8 to meet regularly to advise the director-general whether to declare an emergency, take necessary
steps to avert a crisis, or both. The complexities and apparent increased frequency of emerging infectious disease threats, and the
catastrophic consequences of delays in the international response,
make it no longer tenable to place the sole responsibility and authority with the WHO’s director-general to convene currently ad hoc
emergency committees. As the WHO begins the election campaign for a new director-general, it is an opportune moment to
strengthen its capacity and leadership in global health security.
The UN’s high-level panel on the global health crises called Ebola
a “preventable tragedy.” If the ongoing panepidemics of Zikacaused neurological syndromes or yellow fever eventually lead to
catastrophic consequences, then the panel’s admonition could come
true: “If the WHO does not successfully reform, the next major pandemic will cause thousands of otherwise preventable deaths. This
may be the last opportunity to ensure that the WHO is empowered
to build an effective emergency preparedness and response capacity with the necessary political leadership. Another failure to perform may necessitate consideration of alternate UN institutional response mechanisms.”9
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